The company is developing biologics across three internal programs BOSTON, Nov. 10, 2020 /PRNewswire/ -- The leading company in site-spec...
EMPOWERING
PROTEIN ENGINEERING
Site-specific modification of proteins through unique genetic code expansion platform
UNIQUE BIOCONJUGATION PLATFORM
BrickBio's platform enables custom tailoring of any protein with homogenous site-specific and site-selective modifications for both research and therapeutic applications. This technology further expands the protein engineering life cycle by developing unique biologics that wouldn’t exist otherwise.
OUR
TECHNOLOGY
PROTEIN ENGINEERING
Improve protein characteristics, such as increasing serum half-life, improved specificity, or boosted activity.
BIOCONJUGATION KITS
RUO kits are available for a variety of applications: dye-linked, oligo-linked,
and immuno-based assays
PHARMA PARTNERSHIPS
Development of custom protein-based therapeutics or research assays to drastically improve R&D productivity.
ANTIBODY CONJUGATION
Empowering the next generation of ADCs with improved efficacy, dosage, and modification homogeneity
IN VIVO CELL BASED ASSAYS
Investigation of protein half-life or
protein-protein interactions in vivo with
high temporal control
THERAPEUTIC PIPELINE
We are currently developing early-stage biologic therapeutic candidates with improved characteristics
RECENT NEWS
BrickBio has made robust its novel site-specific conjugation process of inserting unnatural amino acids at any site within a protein or a...
BOSTON, Jan. 22, 2020 /PRNewswire/ -- BrickBio Inc., the leading company in site specific, single and multi-site bioconjugation of protei...
Therapeutic Pipeline
OUR TEAM
CEO, Co-Founder,
TIGER GENE
VP, COMMERCIAL
DEVELOPMENT
SENIOR ADVISOR &
CHAIRMAN OF SAB
HEAD OF BUSINESS DEVELOPMENT
CONTACT
BRICKBIO
OUR ADDRESS
12 Gill Street, Suite 4200
Woburn, MA, 01801, USA
For any general inquiries, please fill in the following contact form:
